Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Summary

Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment to remove clot within 12 hours following stroke onset. Neu2000KWL will be administered before endovascular treatment.

Timeline

Start

2021-12-25

Primary completion

2024-06

Completion

2025-01

Outcome

Missed primary endpoint

paper In this randomized clinical trial, nelonemdaz did not meet the primary efficacy end point compared with placebo. PMID 39874036 ↗

Publications

• Lee JS, Kang HG, Ahn SH, Song TJ, Shin DI, Bae HJ, Kim CH, Heo SH, Cha JK, Lee YB, Kim EG, Park MS, Park HK, Kim J, Yu S, Mo H, Sohn SI, Kwon JH, Kim JG, Kim YS, Choi JC, Hwang YH, Jung KH, Kim SK, Seo WK, Seo JH, Yoo J, Chang JY, Park M, Lee JS, San An C, Gwag BJ, Choi DW, Kwon SU. Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial. JAMA Netw Open. 2025 Jan 2;8(1):e2456535. doi: 10.1001/jamanetworkopen.2024.56535.
• Lee JS, Lee JS, Gwag BJ, Choi DW, An CS, Kang HG, Song TJ, Ahn SH, Kim CH, Shin DI, Kwon SU. The Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz (RODIN) Trial: Protocol for a Double-Blinded Clinical Trial of Nelonemdaz in Patients with Hyperacute Ischemic Stroke and Endovascular Thrombectomy. J Stroke. 2023 Jan;25(1):160-168. doi: 10.5853/jos.2022.02453. Epub 2023 Jan 31.

Drugs

Indications